# Inmune Bio, Inc.: financial statements, quarterly

INMB · Nasdaq · CIK 1711754 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/inmb.md) · [Financials](/companies/inmb/financials.md) · [Filings](/companies/inmb/filings.md) · [Insiders](/companies/inmb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/inmb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001213900-24-092861.md) | [0.0 d](/filings/0001013762-25-003354.md) | [0.0](/filings/0001213900-25-041072.md) | [0.0 d](/filings/0001213900-25-073077.md) | [0.0 d](/filings/0001213900-25-104141.md) | [0.0 d](/filings/0001213900-26-036370.md) | [0.1](/filings/0001213900-26-053338.md) | [0.0 d](/filings/0001213900-26-086135.md) | [0.0 d](/filings/0001213900-25-104141.md) | [0.0 d](/filings/0001213900-26-036370.md) | not reported | not reported |
| Research and development | $m | [6.0](/filings/0001213900-24-092861.md) | [6.0 d](/filings/0001013762-25-003354.md) | [8.7](/filings/0001213900-25-041072.md) | [7.1](/filings/0001213900-25-073077.md) | [10.1](/filings/0001213900-25-104141.md) | [7.4 d](/filings/0001213900-26-036370.md) | [7.6](/filings/0001213900-26-053338.md) | [5.8](/filings/0001213900-25-073077.md) | [4.9](/filings/0001213900-25-104141.md) | [2.3 d](/filings/0001213900-26-036370.md) | [3.6](/filings/0001213900-26-053338.md) | not reported |
| Operating income | $m | [(8.5)](/filings/0001213900-24-092861.md) | [(8.4) d](/filings/0001013762-25-003354.md) | [(11.0)](/filings/0001213900-25-041072.md) | [(9.9)](/filings/0001213900-25-073077.md) | [(12.3)](/filings/0001213900-25-104141.md) | [(9.5) d](/filings/0001213900-26-036370.md) | [(9.9)](/filings/0001213900-26-053338.md) | [(24.6)](/filings/0001213900-26-086135.md) | [(7.4)](/filings/0001213900-25-104141.md) | [(5.5) d](/filings/0001213900-26-036370.md) | [(5.8)](/filings/0001213900-26-053338.md) | [(1.5)](/filings/0001213900-26-086135.md) |
| Interest expense | $m | [0.6](/filings/0001213900-24-092861.md) | [0.5 d](/filings/0001013762-25-003354.md) | [0.4](/filings/0001213900-24-041286.md) | [0.3](/filings/0001213900-24-064076.md) | [0.1](/filings/0001213900-24-092861.md) | [(0.4) d](/filings/0001213900-25-041072.md) | [0.0](/filings/0001213900-25-041072.md) | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(8.6)](/filings/0001213900-24-092861.md) | [(8.4) d](/filings/0001013762-25-003354.md) | [(11.0)](/filings/0001213900-25-104141.md) | [(9.7)](/filings/0001213900-25-104141.md) | [(12.1)](/filings/0001213900-25-104141.md) | [(9.2) d](/filings/0001213900-26-036370.md) | [(9.7)](/filings/0001213900-26-086135.md) | [(24.5)](/filings/0001213900-26-086135.md) | [(6.5)](/filings/0001213900-25-104141.md) | [(5.3) d](/filings/0001213900-26-036370.md) | [(5.4)](/filings/0001213900-26-086135.md) | [(1.3)](/filings/0001213900-26-086135.md) |
| Diluted EPS | $ per share | [(0.48)](/filings/0001213900-24-092861.md) | not reported | [(0.61)](/filings/0001213900-25-041072.md) | [(0.50)](/filings/0001213900-25-073077.md) | [(0.60)](/filings/0001213900-25-104141.md) | not reported | [(0.43)](/filings/0001213900-26-053338.md) | [(1.05)](/filings/0001213900-26-086135.md) | [(0.24)](/filings/0001213900-25-104141.md) | not reported | [(0.20)](/filings/0001213900-26-053338.md) | [(0.05)](/filings/0001213900-26-086135.md) |
| Basic EPS | $ per share | [(0.48)](/filings/0001213900-24-092861.md) | not reported | [(0.61)](/filings/0001213900-25-041072.md) | [(0.50)](/filings/0001213900-25-073077.md) | [(0.60)](/filings/0001213900-25-104141.md) | not reported | [(0.43)](/filings/0001213900-26-053338.md) | [(1.05)](/filings/0001213900-26-086135.md) | [(0.24)](/filings/0001213900-25-104141.md) | not reported | [(0.20)](/filings/0001213900-26-053338.md) | [(0.05)](/filings/0001213900-26-086135.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [41.8](/filings/0001213900-23-082167.md) | [35.8](/filings/0001013762-25-003354.md) | [26.0](/filings/0001213900-24-041286.md) | [31.1](/filings/0001213900-24-064076.md) | [33.6](/filings/0001213900-24-092861.md) | [20.9](/filings/0001213900-26-036370.md) | [19.3](/filings/0001213900-25-041072.md) | [33.4](/filings/0001213900-25-073077.md) | [27.7](/filings/0001213900-25-104141.md) | [24.8](/filings/0001213900-26-036370.md) | not reported | not reported |
| Current assets | $m | [45.6](/filings/0001213900-23-082167.md) | [39.9](/filings/0001013762-25-003354.md) | [29.8](/filings/0001213900-24-041286.md) | [35.5](/filings/0001213900-24-064076.md) | [35.9](/filings/0001213900-24-092861.md) | [22.7](/filings/0001213900-26-036370.md) | [21.0](/filings/0001213900-25-041072.md) | [36.0](/filings/0001213900-25-073077.md) | [30.7](/filings/0001213900-25-104141.md) | [29.9](/filings/0001213900-26-086135.md) | [22.8](/filings/0001213900-26-053338.md) | [23.8](/filings/0001213900-26-086135.md) |
| Total assets | $m | [62.7](/filings/0001213900-23-082167.md) | [57.0](/filings/0001013762-25-003354.md) | [46.8](/filings/0001213900-24-041286.md) | [52.5](/filings/0001213900-24-064076.md) | [52.8](/filings/0001213900-24-092861.md) | [39.6](/filings/0001213900-26-036370.md) | [37.8](/filings/0001213900-25-041072.md) | [37.7](/filings/0001213900-25-073077.md) | [33.4](/filings/0001213900-25-104141.md) | [32.4](/filings/0001213900-26-086135.md) | [25.8](/filings/0001213900-26-053338.md) | [26.8](/filings/0001213900-26-086135.md) |
| Current liabilities | $m | [14.4](/filings/0001213900-23-082167.md) | [18.5](/filings/0001013762-25-003354.md) | [17.5](/filings/0001213900-24-041286.md) | [15.1](/filings/0001213900-24-064076.md) | [13.8](/filings/0001213900-24-092861.md) | [7.2](/filings/0001213900-26-036370.md) | [7.9](/filings/0001213900-25-041072.md) | [8.6](/filings/0001213900-25-073077.md) | [7.4](/filings/0001213900-25-104141.md) | [8.4](/filings/0001213900-26-086135.md) | [5.4](/filings/0001213900-26-053338.md) | [5.9](/filings/0001213900-26-086135.md) |
| Total liabilities | $m | [18.0](/filings/0001213900-23-082167.md) | [18.9](/filings/0001013762-25-003354.md) | [17.8](/filings/0001213900-24-041286.md) | [15.4](/filings/0001213900-24-064076.md) | [14.1](/filings/0001213900-24-092861.md) | [7.5](/filings/0001213900-26-036370.md) | [8.1](/filings/0001213900-25-041072.md) | [8.8](/filings/0001213900-25-073077.md) | [8.0](/filings/0001213900-25-104141.md) | [8.8](/filings/0001213900-26-086135.md) | [6.2](/filings/0001213900-26-053338.md) | [6.5](/filings/0001213900-26-086135.md) |
| Long-term debt | $m | [12.5](/filings/0001213900-23-082167.md) | not reported | not reported | not reported | not reported | [15.0](/filings/0001013762-25-003354.md) | [15.0](/filings/0001213900-25-041072.md) | [15.0](/filings/0001213900-25-073077.md) | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [9.9](/filings/0001013762-25-003354.md) | [7.5](/filings/0001213900-24-041286.md) | [5.0](/filings/0001213900-24-064076.md) | [2.5](/filings/0001213900-24-092861.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [43.9](/filings/0001213900-24-092861.md) | [37.3](/filings/0001213900-26-036370.md) | [28.2](/filings/0001213900-25-104141.md) | [36.3](/filings/0001213900-25-104141.md) | [38.7](/filings/0001213900-25-104141.md) | [32.1](/filings/0001213900-26-086135.md) | [29.7](/filings/0001213900-26-086135.md) | [28.9](/filings/0001213900-26-086135.md) | [25.4](/filings/0001213900-25-104141.md) | [23.5](/filings/0001213900-26-086135.md) | [19.6](/filings/0001213900-26-086135.md) | [20.4](/filings/0001213900-26-086135.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.3) d](/filings/0001213900-24-092861.md) | [(3.4) d](/filings/0001013762-25-003354.md) | [(7.5)](/filings/0001213900-25-041072.md) | [(7.9) d](/filings/0001213900-25-073077.md) | [(7.0) d](/filings/0001213900-25-104141.md) | [(11.0) d](/filings/0001213900-26-036370.md) | [(6.8)](/filings/0001213900-26-053338.md) | [(7.4) d](/filings/0001213900-26-086135.md) | [(5.4) d](/filings/0001213900-25-104141.md) | [(2.9) d](/filings/0001213900-26-036370.md) | [(3.4)](/filings/0001213900-26-053338.md) | [(3.2) d](/filings/0001213900-26-086135.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.2 d](/filings/0001213900-25-104141.md) | [0.1 d](/filings/0001213900-26-036370.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [17.9](/filings/0001213900-23-082167.md) | [17.9](/filings/0001213900-24-041286.md) | [17.9](/filings/0001213900-24-064076.md) | [18.0](/filings/0001213900-24-092861.md) | [18.0](/filings/0001213900-25-041072.md) | [19.3](/filings/0001213900-25-073077.md) | [20.2](/filings/0001213900-25-104141.md) | [22.5](/filings/0001213900-26-053338.md) | [23.3](/filings/0001213900-26-086135.md) | [26.6](/filings/0001213900-25-104141.md) | [26.6](/filings/0001213900-26-053338.md) | [26.7](/filings/0001213900-26-086135.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 27,753,789 at 2026-08-06, from the cover of the [10-Q filed 2026-08-06](/filings/0001213900-26-086135.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.